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Abstract
Background: Myasthenia gravis is an autoimmune disorder characterized by production of acetylcholine receptor antibodies.
These antibodies are mainly produced by thymic B-lymphocytes.
Objective: Our aim was to detect the correlation between thymic pathology and outcome of myasthenia gravis. Moreover, we tried
to detect the involvement of survivin as an apoptosis inhibitor in pathogenesis of myasthenia.
Patients and methods: This study was a prospective study conducted on 36 non thymomatous myasthenic patients subjected to
thymectomy. Patients were followed for 6 months after operation. Moreover, 36 control normal thymic specimens were obtained
from patients operated for open heart surgery. Resected thymic tissue was sent for histopathological examination and immuno-
histochemical staining by survivin to examine its role in pathogenesis of myasthenia.
Results: Patients were divided into group A with hyperplastic thymus and group B with atrophic thymus. Nine patients had no
improvement after surgery and the remaining had variable degrees of clinical improvement. Pathology of thymus did not affect
clinical outcome with significant improvement in both groups.
Decreased duration of symptoms before surgery and female sex are statistically associated with more improvement of patients'
symptoms. Positive expression of survivin was detected in germinal centers of all hyperplastic and atrophic thymuses. All the
control thymuses were negative for survivin expression.
Conclusion: Thymectomy for myasthenia gravis is an effective and beneficial procedure even in patients with atrophic thymus.
Survivin is expressed in all myasthenic thymuses confirming its role in pathogenesis of myasthenia gravis.
Copyright © 2016, Publishing services by Elsevier B.V. on behalf of The Egyptian Society of Cardio-thoracic Surgery. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Myasthenia gravis is an autoimmune disorder characterized by production of acetylcholine receptor antibodies
against acetylcholine receptors resulting in weakness of skeletal muscle starting from ocular muscle and extending to
generalized weakness and respiratory failure [1]. These antibodies are mainly produced by thymic B-lymphocytes [2].
Medical treatment of myasthenia gravis involves the use of anticholinesterase agents, immunosuppressive drugs,
plasmapheresis, corticosteroids and gamma globulin, with clinical remission rates up to 15% of cases [3]. Moreover,
thymectomy was settled as an accepted other modality for treatment of myasthenia gravis since Blalock et al. in 1939
who published their series of patients showing improvement of symptoms after thymectomy [4]. Pathology of resected
thymus and its correlation to outcome and pathogenesis of myasthenia had much debates in literature.
One theory supported the role of thymus in pathogenesis of myasthenia gravis by production of inhibitors to
apoptosis like survivin that prevent autoreactive B-cell death [5]. In our study we aimed to detect the correlation
between thymic pathology and outcome of myasthenia gravis after thymectomy. Moreover, we tried to detect the
involvement of survivin as an apoptosis inhibitor in pathogenesis of myasthenia gravis.2. Patients and methods
This study is a prospective study conducted on 36 non thymomatous myasthenic patients who were subjected to
thymectomy in Tanta University Hospital during the period from January 2013 till July 2015. Informed consent was
taken from all patients involved in the study. All patients were followed up for at least 6 months after operation
regarding clinical improvement. Diagnosis of myasthenia gravis in our study was based on clinical examination by
neurologist to confirm myasthenia symptoms and elevated acetylcholine receptor antibody titre. Complete history
taking was recorded including age, sex, number of myasthenic crisis and duration of symptoms before surgery. Pa-
tients were classified into 4 classes according to Osserman classification [6]:
Class I: with ocular involvement only
Class IIA: mild generalized weakness with slow progression and gradual involvement of bulbar and skeletal
muscles
Class IIB: moderate generalized weakness with gradual progression to more severe form
Class III: acute fulminant form with rapid progression of disease and acute involvement of respiratory muscle
Class IV: Late severe form with acute progressive symptoms started 2 years after onset of myasthenia.
Chest X-ray and CT chest with contrast were done to all patients before surgery to evaluate thymus size. Indications
for surgery in our study were persistent generalized myasthenic symptoms despite appropriate medical therapy and
ocular myasthenic patients unresponsive to treatment. All patients were subjected to at least 3 sessions of plasma-
pharesis, the last onewas 48 h before operation. Patients with thymomatous myasthenia gravis were excluded from the
study as those patients were candidate for surgery due to thymoma itself.
During operation complete sternotomy was done, all thymic tissues and anterior mediastinal fat were resected from
one phrenic nerve to the other phrenic nerve and from diaphragm till cervical thymus. Patients were extubated in the
operating room and transferred to ICU.
Resected thymic tissue was sent for histopathological examination to detect thymic pathology using ordinary
hematoxylin and eosin staining. According to pathologic results, Patients were divided into group Awith hyperplastic
thymus and group B with atrophic thymus.
All patients in our study were followed up for at least 6 months post thymectomy in neurology clinic to detect
degree of improvement of myasthenic symptoms after thymectomy. Patients were graded into 5 grades according to
the DeFilippi classification [7] Class I: Complete remission; no medications, Class 2: remission with decreased
medication, Class 3: Improvement in symptoms with decreased medications, Class 4: No improvement in symptoms
or medications and Class 5: Worsening of symptoms. For statistical analysis due to limited number of patients, we
considered patients class I, II, and III as improved patients and class 4 and 5 as patients with no improvement.
In our study, we tried to detect the role of survivin as an immunomodulator marker in the pathogenesis of
myasthenia gravis. Beside thymic specimens obtained from myasthenic patients, thirty-six control normal thymicPlease cite this article in press as: Abo Elnasr MM et al., Thymectomy in non thymomatous myasthenia gravis: Impact of pathology on outcome
and role of survivin in pathogenesis, Journal of the Egyptian Society of Cardio-Thoracic Surgery (2016), http://dx.doi.org/10.1016/
j.jescts.2016.11.002
Fig. 1. Normal thymus composed of a cortex and medulla showing Hassal corpuscle (H&E  200).
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also from those patients regarding sharing in the study as a control group (Fig. 1).
All thymic sections from myasthenic and control groups were subjected to immunohistochemical staining by
survivin. After standard deparaffinization, hydration, and blocking of endogenous peroxidase, they were processed in
a microwave oven twice (5 min each) at high power. Subsequently, a standard streptavidinebiotin-peroxidase
technique was applied to detect the antigens. Sections were incubated with anti-survivin (Clone 12C4, 1:100, Dako
Corp, USA), for 30 min at room temperature. Diaminobenzidine (DAB) was used as the chromogen. Nuclear
brownish staining for survivin was considered positive.
Statistical analysiswas performedusingStatistical Package for Social Science (SPSSversion16).Datawere expressed
in terms of frequencies and percentages for categorical variables and mean þ standard deviation (þSD) for continuous
variables. For comparing categorical data, Chi-square (X2) test was performed. Fisher's exact test was performed if one ofTable 1
Patients characters.
Number (%)
Age (mean ± SD) 26.64 ± 5.69
Sex
Male 13 (36.1)
Female 23 (63.9)
Osserman class
Class I 4 (11.1)
Class IIA 20 (55.6)
Class IIB 8 (22.2)
Class III 3 (8.3)
Class IV 1 (2.8)
Durations of symptoms (mean ± SD) 13.11 ± 6.72
Response to treatment
Complete improvement without medication 4 (11.1)
Complete improvement with medications 11 (30.6)
Partial improvement with mediation 12 (33.3)
No improvement 9 (25)
Preoperative myasthenic crisis
Yes 3 (8.3)
No 33 (91.7)
Presence of ectopic thymic tissue
Yes 11 (30.6)
No 25 (69.4)
Postoperative medication
AChE inhibitors þ corticosteroids 10 (27.8)
AChE inhibitors only 26 (72.2)
AChE inhibitors: Acetylcholinesterase inhibitors.
Please cite this article in press as: Abo Elnasr MM et al., Thymectomy in non thymomatous myasthenia gravis: Impact of pathology on outcome
and role of survivin in pathogenesis, Journal of the Egyptian Society of Cardio-Thoracic Surgery (2016), http://dx.doi.org/10.1016/
j.jescts.2016.11.002
Fig. 2. Atrophic thymus: The thymic tissue is replaced by prominent adipose tissue with presence of numerous lymphoid follicles showing
prominent germinal centers (H&E  100).
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variable, ManneWhitney U test was used. P values of <0.05 were considered statistically significant.
3. Results
This study is a prospective study conducted on 36 patients diagnosed to have non thymomatous myasthenia
gravis and subjected to transsternal thymectomy. The mean age of patients enrolled in the study was 26.64 ± 5.69.
Twenty-three patients were female. According to Osserman classification: 4 patients were in class I, 20 patients in
class IIA, 8 patients in class IIB, 3 patients in class III and 1 patient in class IV. Patients were followed up for at
least 6 months after surgery for clinical improvement. Nine patients had no improvement after surgery and theTable 2
Comparison of patients with atrophic versus hyperplastic thymus.
N
Total ¼ 36
Hyperplastic thymus
N ¼ 24 (100%)
Atrophic thymus
N ¼ 12 (100%)
P value
Age Mean ± SD 25.46 ± 6.35 29 ± 2.86 0.114
Sex 0.220
Female 23 17 (70.8) 6 (50)
Male 13 7 (29.2) 6 (50)
Osserman class 0.866
Class I 4 3 (12.5) 1 (8.3)
Class IIA 20 12 (50) 8 (66.7)
Class IIB 8 6 (25) 2 (16.7)
Class III 3 2 (8.3) 1 (8.3)
Class IV 1 1 (4.2) 0 (0)
Durations of symptoms Mean ± SD 13.13 ± 7.38 13.08S ± 5.14 0.394
Response to treatment 0.443
Improvement 27 19 (79.2) 8 (66.7)
No improvement 9 5 (20.8) 4 (33.3)
Preoperative myasthenic crisis 0.536
Yes 3 3 (12.5) 0 (0)
No 33 21 (87.5) 12 (100)
Presence of ectopic thymic tissues 0.020*
Yes 11 4 (16.67) 7 (58.33)
No 25 20 (83.33) 5 (41.67)
Postoperative medication 0.700
AChE inhibitors þ corticosteroids 10 6 (25) 4 (33.3)
AChE inhibitors only 26 18 (75) 8 (66.7)
*statistically significant p value <0.05. AChE inhibitors: Acetylcholinesterase inhibitors.
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Table 3
Predictors of patients' improvement after surgery.
Total
N ¼ 36
Improvement
N ¼ 27 (%)
No improvement
N ¼ 9 (%)
P value
Age (Mean ± SD) 26.59 ± 5.85 26.78 ± 5.20 0.944
Sex 0.046*
Female 23 20 (86.96) 3 (13.04)
Male 13 7 (53.85) 6 (46.15)
Osermann class 0.231
Class I 4 4 (100) 0 (0)
Class IIA 20 14 (70) 6 (30)
Class IIB 8 6 (75) 2 (25)
Class III 3 3 (100) 0 (0)
Class IV 1 0 (0) 1 (100)
Durations of symptoms* Mean ± SD 11.22 ± 5.30 18.78 ± 7.31 0.01*
Preoperative myasthenic crisis 0.558
Yes 3 3 (100) 0 (0)
No 33 24 (72.73) 9 (27.27)
Presence of ectopic thymic tissues 0.409
Yes 11 7 (63.64) 4 (36.36)
No 25 20 (80) 5 (20)
Postoperative medication 0.226
AChE inhibitors þ corticosteroids 10 6 (60) 4 (40)
AChE inhibitors only 26 21 (80.77) 5 (19.23)
*Statistically significant p value (<0.05). AChE inhibitors: Acetylcholinesterase inhibitors.
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characters are shown in Table 1.
Patients in our study were divided into group Awith hyperplastic thymus, which was characterized by presence of
lymph follicles with germinal centers in the medulla, and group B with atrophic thymus, which was characterized by a
decrease in cortical lymphocytes, thinning and irregularity of the cortex, loss of corticomedullary demarcation, and
infiltration by adipose tissue in connective tissue capsule and septae. Some lymphoid follicles with germinal center
were persisted in atrophic thymuses (Fig. 2).
We found that pathology of thymus did not affect clinical outcome with significant improvement in both groups.
We noticed that there was more ectopic thymic tissue in the atrophic group (Table 2).
By analysis of other factors that may be associated with improvement of myasthenic symptoms after thymectomy,
we found that decreased duration of symptoms before surgery and female sex are statistically associated with more
improvement of patients' symptoms, otherwise no other factors were associated with improvement (Table 3).
Moreover, we studied immunohistochemical expression of survivin in thymus of non-thymomatous myasthenic
patients (Fig. 2). Positive expression of survivin was detected in germinal centers of all hyperplastic thymuses as well
as in some scattered cells in the medulla. Also, cells in the germinal centers persisted in atrophic thymus stained
positively for survivin. All the control thymuses were negative for survivin expression (Fig. 3).
4. Discussion
Thymectomy is an accepted treatment modality for myasthenia gravis [8]. The response of patients to surgery is
highly variable and depends on many factors like age, sex, duration of symptoms before surgery, preoperative class of
myasthenia, surgical approach, presence of ectopic thymus tissue and pathology of thymus. In our study we tried to
address these factors with special emphasis on pathology of thymus as prognosticator to clinical outcome.
Histologically, Thymus is composed of cortex and medulla containing lymphocytes that are the site of production
of autoantibodies against acetylcholine receptors. It contains also perivascular spaces that are composed of adipose
tissue and have no role in the immune process [9]. Atrophic thymus is mainly due to an aging process with formation
of more adipose tissue reducing the autoimmune activity of thymus [10,11].
Pathology of thymus was found in different studies to play a role in patient outcome after surgery with hyperplastic
thymus achieving the best prognosis and atrophic thymus had less favorable one [12,13].Please cite this article in press as: Abo Elnasr MM et al., Thymectomy in non thymomatous myasthenia gravis: Impact of pathology on outcome
and role of survivin in pathogenesis, Journal of the Egyptian Society of Cardio-Thoracic Surgery (2016), http://dx.doi.org/10.1016/
j.jescts.2016.11.002
Fig. 3. Immunohistochemical expression of survivin. a) Hyperplastic thymus showing positive nuclear expression of survivin in the germinal
center (immunoperoxidase 400). b) Atrophic thymus showing positive nuclear expression of survivin in the germinal center (immunoperoxidase
400) c) Control thymus negative for survivin expression (immunoperoxidase 100).
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mectomy with no significant difference between atrophic and hyperplastic thymus regarding patient outcome after
surgery. Actually, these finding were beyond our expectation and supported the idea that role of thymus in myasthenia
gravis is still unclear. Our results were similar to findings by Budde et al. who concluded that pathology of thymus is
not a predictor of improvement after surgery [14]. Similar data were given by Pompeo et al., Spillane et al. and
Mantegazza et al. who found that no effect of thymus pathology on prognosis [15e17]. Chen et al. in their study,
comparing clinical features and immune responses of atrophic versus hyperplastic thymus, found that atrophy of
thymus did not decrease rate of complete remission of myasthenia gravis after thymectomy and atrophic thymus may
have a role in progression of myasthenia gravis [18]. Our study and all these previous mentioned studies support the
role of thymectomy in any patient with myasthenia gravis regardless of size of thymus or its pathology.
In our study, we observed the presence of more ectopic mediastinal thymic tissue in atrophic group. This is similar
to data given by Chen et al. who observed more ectopic thymic tissue in patients with atrophic thymus [18]. The
relationship between the presence of more ectopic thymic tissue and atrophic thymus is not well defined. However,
one theory suggested the possibility of secretion of cytotoxic T-lymphocytes from ectopic tissue that is directed to
thymic epithelial cells replacing thymic stroma making it atrophic [19].
Moreover, El-Medany et al. found that ectopic thymic tissue was a predictor of improvement of myasthenia gravis
[20] and Sonette et al. documented that remission was associated with more thymic tissue removal [21].Please cite this article in press as: Abo Elnasr MM et al., Thymectomy in non thymomatous myasthenia gravis: Impact of pathology on outcome
and role of survivin in pathogenesis, Journal of the Egyptian Society of Cardio-Thoracic Surgery (2016), http://dx.doi.org/10.1016/
j.jescts.2016.11.002
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decreased duration of symptoms before surgery and female sex are predictors of improvement. Decreased duration
of symptoms were documented also by Tansel et al. and Sonette et al. to be associated with better remission rate
[21,22]. Venuta et al. found that reduced duration of symptoms less than 18 months was linked to more
improvement of symptoms [23]. Despite previous findings, Jaretzki et al. found in their study that shorter duration
of symptoms did not affect prognosis [24]. Female sex, in our study, was statistically correlated with better
improvement of symptoms and this is similar to studies by First et al., Masaoka et al. and Mowafy who found that
female sex had better outcome [25e27].
Another important issue, in our study, was to detect the role of thymus in pathogenesis of myasthenia and the exact
cause that mediate myasthenia development. Myasthenia gravis is considered as T-cell dependent, B-cell mediated
disease. Several reports addressed the idea of immunostaining of resected thymus in an attempt to discover exactly
what promotes immune process in myasthenia gravis. A pilot study by Piemani et al. involved histopathological
examination of thymus specimens found that T cells expressed CD 3, CD 43, and CD 5. All T cells also expressed Bcl-
2, which is an anti-apoptotic marker and is usually present in T cells of lymphoid tissues [28].
Chen et al., in their study, evaluated the markers of B- cell activation in both atrophic and hyperplastic thymus and
found that increased expression of CD-19 and CD-21 in thymic specimens in myasthenic patients than control group
irrespective of thymic pathology [18].
In our study, we chose survivin which is an antiapoptotic protein that prevents programmed cell death to test its role
in myasthenia gravis. Survivin has been expressed in certain cancers like esophageal carcinoma. Its detection in
malignancy was associated with improved prognosis by application of anti-tumor vaccine strategy.
It plays an important role in pathogenesis of certain autoimmune disease like rheumatoid arthritis and multiple
sclerosis. Our study is the second study after Kusner et al. that tested survivin expression in myasthenia gravis. We
compared between thymic specimens of myasthenic patients and those of non myasthenic patients subjected to open
heart surgery. Survivin expression was evident in all myasthenic patients either atrophic or hyperplastic and we failed
to detect it in control group indicating the close association between survivin expression and pathogenesis of
myasthenia gravis. Moreover, Kusner et al. extended their study on rat models that were vaccinated with antisurvivin
showing reduction of circulating autoantibodies against acetylcholine receptors [5]. This may create a new hope in the
future towards invention of a new vaccine against myasthenia gravis with better outcome.
From our study, we can conclude that thymectomy for non thymomatous myasthenia gravis is an effective and
beneficial procedure with good results even in patients with atrophic thymus. Survivin is expressed in all myasthenic
thymuses either atrophic or hyperplastic confirming its role in pathogenesis of myasthenia gravis.Conflict of interest
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